Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Active not recruiting 5Not yet recruiting 3Recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 2Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

Carboplatin 127Cisplatin 125Drug Therapy 117Bevacizumab 102Oxaliplatin 99Capecitabine 99Radiotherapy 97Gemcitabine 87tislelizumab 86Paclitaxel 86Cyclophosphamide 86Specimen Handling 80pembrolizumab 76toripalimab 68Magnetic Resonance Spectroscopy 65Fluorouracil 63Injections 62sintilimab 58Surgical Procedures, Operative 58anlotinib 53Docetaxel 52130-nm albumin-bound paclitaxel 50fludarabine 47Standard of Care 46Pemetrexed 45Immune Checkpoint Inhibitors 45Blood Specimen Collection 43Biopsy 43venetoclax 42Leucovorin 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × Imlunestrant × Clear all
NCT07287098 2026-05-22

preEMBER

Eli Lilly and Company

Phase 2 Not yet recruiting
600 enrolled
Breast

Breast Neoplasms

NCT07410559 2026-02-18

Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer

Fudan University

Phase 2 Not yet recruiting
189 enrolled
Breast

Breast Neoplasms

NCT07191717 2025-11-10

Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial

Jonsson Comprehensive Cancer Center

Phase 2 Not yet recruiting
42 enrolled
Breast

Anatomic Stage I Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡